GSK Australia
Issued: Monday 3 April, 2023
- Nucala is the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with nasal polyps1,2
- Chronic rhinosinusitis is a common chronic respiratory disease that affects one in ten Australians.3 An estimated 25-30% of people living with chronic rhinosinusitis also have nasal polyps (soft jelly-like tissue growths within the nasal cavity)4,5
- The availability of Nucala on the PBS for CRSwNP provides subsidised access to a new treatment option for these patients
- Video news release available here.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
